Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory
Open Access
- 21 September 2016
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (9) , 1591
Abstract
Two types of reverse vaccinology (RV) should be distinguished: genome-based RV for bacterial vaccines and structure-based RV for viral vaccines. Structure-based RV consists in trying to generate a vaccine by first determining the crystallographic structure of a complex between a viral epitope and a neutralizing monoclonal antibody (nMab) and then reconstructing the epitope by reverse molecular engineering outside the context of the native viral protein. It is based on the unwarranted assumption that the epitope designed to fit the nMab will have acquired the immunogenic capacity to elicit a polyclonal antibody response with the same protective capacity as the nMab. After more than a decade of intensive research using this type of RV, this approach has failed to deliver an effective, preventive HIV-1 vaccine. The structure and dynamics of different types of HIV-1 epitopes and of paratopes are described. The rational design of an anti-HIV-1 vaccine is shown to be a misnomer since investigators who claim that they design a vaccine are actually only improving the antigenic binding capacity of one epitope with respect to only one paratope and not the immunogenic capacity of an epitope to elicit neutralizing antibodies. Because of the degeneracy of the immune system and the polyspecificity of antibodies, each epitope studied by the structure-based RV procedure is only one of the many epitopes that the particular nMab is able to recognize and there is no reason to assume that this nMab must have been elicited by this one epitope of known structure. Recent evidence is presented that the trimeric Env spikes of the virus possess such an enormous plasticity and intrinsic structural flexibility that it is it extremely difficult to determine which Env regions are the best candidate vaccine immunogens most likely to elicit protective antibodies.Keywords
This publication has 202 references indexed in Scilit:
- Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogensBiochemical and Biophysical Research Communications, 2012
- Induction of Immunity to Human Immunodeficiency Virus Type-1 by VaccinationImmunity, 2010
- An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120Virology, 2010
- Rational antibody-based HIV-1 vaccine design: current approaches and future directionsCurrent Opinion in Immunology, 2010
- Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogensBiochemical and Biophysical Research Communications, 2009
- Mimicking the Structure of the V3 Epitope Bound to HIV-1 Neutralizing AntibodiesBiochemistry, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Polyspecificity of T cell and B cell receptor recognitionSeminars in Immunology, 2007
- The Broad Antibacterial Activity of the Natural Antibody Repertoire Is Due to Polyreactive AntibodiesCell Host & Microbe, 2007
- Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signalingJournal of Molecular Recognition, 2005